PanGenomic Health, Inc. Class A AI Stock Analysis
Want to see TSE:NARA full AI Analyst Report?
PanGenomic Health, Inc. Class A (NARA) AI Stock Analysis
PanGenomic Health, Inc. Class A
(CNQX:NARA)
The score is primarily constrained by persistent pre-revenue losses, negative equity, and ongoing cash burn. Weak price trends and limited valuation support further reduce the score, despite modest positive technical signals from MACD and the stochastic indicator.
PanGenomic Health, Inc. Class A (NARA) vs. iShares MSCI Canada ETF (EWC)
- Market Cap
- CAD 2.53M
- Dividend Yield
- ―
- Average Volume (3M)
- 15.96K
- Price to Earnings (P/E)
- -1.4
- Beta (1Y)
- -0.13
- Revenue Growth
- ―
- EPS Growth
- 43.30%
- Country
- Canada
- Employees
- 0
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Healthcare Information Services
PanGenomic Health, Inc. Class A Business Overview & Revenue Model
Company Description
Pangenomic Health Inc. is a precision health company that has developed a self-care digital platform to deliver personalized, evidence-based information about natural treatments to support mental health. The company's mobile app, the Nara App, provid...
PanGenomic Health, Inc. Class A Financial Statement Overview
Summary
Very weak financial performance: the company is pre-revenue, consistently loss-making, has negative equity, a very small asset base, and sustained negative operating cash flow. Limited improvement from historical lows does not offset the significant financial risk.
Income Statement
8Very NegativeBalance Sheet
6Very NegativeCash Flow
7Very Negative| Breakdown | TTM | Mar 2026 | Jun 2025 | Jun 2024 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -629 | -628 | ― | -681.43K | -11.11K | -2,127 |
| EBITDA | -4.23M | -3.42M | 7,410 | -2.71M | -3.57M | -847.50K |
| Net Income | -4.25M | -3.43M | -3,803 | -2.97M | -20.35M | -2.65M |
Balance Sheet | ||||||
| Total Assets | 157.72K | 160.91K | 39.16K | 71.48K | 504.14K | 2.58M |
| Cash, Cash Equivalents and Short-Term Investments | 7,717 | 38.77K | 1,307 | 12.56K | 88.53K | 1.35M |
| Total Debt | 715.34K | 212.87K | 0 | 964.75K | 101.77K | 0 |
| Total Liabilities | 2.91M | 2.35M | 2.44M | 2.22M | 719.25K | 334.45K |
| Stockholders Equity | -2.75M | -2.19M | -2.41M | -2.14M | -215.11K | 2.24M |
Cash Flow | ||||||
| Free Cash Flow | -2.21M | -1.88M | -58.25K | -1.57M | -2.79M | -1.07M |
| Operating Cash Flow | -2.21M | -1.88M | -58.25K | -1.57M | -2.78M | -1.06M |
| Investing Cash Flow | 0 | 0 | 0 | -3,142 | -52.13K | -604.91K |
| Financing Cash Flow | 2.21M | 1.92M | 47.00K | 1.50M | 1.57M | 2.97M |
PanGenomic Health, Inc. Class A Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:NARA, the sentiment is Positive. The current price of 0.18 is below the 20-day moving average (MA) of 0.24, below the 50-day MA of 0.24, and below the 200-day MA of 0.35, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 74.76 is Negative, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:NARA.
PanGenomic Health, Inc. Class A Peers Comparison
Overall Rating
TSE:NDAT45Neutral
TSE:NARA42Neutral
TSE:AIDR41Neutral
TSE:DMED39Underperform
TSE:ADK38Underperform
TSE:UDOC38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 45Neutral | CAD 4.13M | -16.67 | -49.83% | ― | ― | 0.00% | |
| 42Neutral | CAD 4.21M | -1.45 | 184.91% | ― | ― | 43.30% | |
| 41Neutral | CAD 32.40M | -1.19 | -444.52% | ― | 415.06% | -54.80% | |
| 39Underperform | CAD 2.63M | -1.29 | 739.84% | ― | ― | -28.35% | |
| 38Underperform | CAD 35.52M | -6.66 | 9999.00% | ― | -36.92% | 13.03% | |
| 38Underperform | CAD 3.45M | -1.06 | 355.56% | ― | 614.03% | 51.97% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TSE:NARA | PanGenomic Health, Inc. Class A | 0.18 | -0.67 | -78.82% | |
| TSE:ADK | Diagnos Inc | 0.23 | -0.09 | -26.56% | |
| TSE:NDAT | nDatalyze Corp | 0.07 | 0.06 | 366.67% | |
| TSE:AIDR | Rocket Doctor Ai Inc | 0.38 | -0.45 | -54.22% | |
| TSE:UDOC | Unidoc Health Corp. | 0.04 | -0.14 | -78.38% | |
| TSE:DMED | DiagnaMed Holdings Corp. | 0.02 | -0.04 | -69.23% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 20, 2026
